DT&CRO (CEO Chaekyu Park) announced on August 22, 2025 that it has signed a strategic Memorandum of Understanding (MOU) with RudaCure (CEO Yongho Kim), a biotech company specializing in novel drug R&D.
This agreement aims to respond to the increasingly sophisticated demand for drug development in the domestic and international pharmaceutical and bio industries, combining the expertise and strengths of both companies to achieve innovative R&D outcomes and global competitiveness.
The importance of strategic collaboration to enhance the efficiency of preclinical and clinical trials and accelerate drug development is growing, and this agreement was planned within this industry trend.
Through this agreement, both companies will closely collaborate in various areas including: ▲discovery and R&D cooperation for novel drug candidates, ▲preclinical and clinical trial planning and execution cooperation, and ▲establishment of data-based analysis and research support systems.
DT&CRO, as a specialized CRO (Contract Research Organization), possesses accumulated experience in preclinical and clinical trial planning and execution, as well as regulatory response capabilities. RudaCure's innovative drug development pipeline (including dry eye disease treatment RCI001 and pain treatment RCI002) and platform technology can achieve synergy effects when combined with DT&CRO's clinical development infrastructure and operational expertise.
CEO Park of DT&CRO stated, "This MOU with RudaCure is expected to create significant synergies in the preclinical and clinical trial fields. Through combining both companies' technologies and know-how, we will contribute to the domestic bio-pharmaceutical industry's leap to the next level."
CEO Kim of RudaCure stated, "Through collaboration with DT&CRO's professional CRO experience and capabilities, we expect to more effectively advance the development of our new drugs including RCI001 and RCI002. We will work together to achieve tangible research outcomes."
